Medtronic (MDT)
NYSEHealth CareMedical - DevicesSnapshot 2026-10-29
$97.11+2.46%
Close 2026-10-29 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put MDT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
Medtronic’s growth in key franchises and new products is the central case. Revenue growth has accelerated, rising from 8.7% to 13.7% year over year. Q1 FY2027 non-GAAP earnings beat estimates, and organic growth guidance rose to 7.25%-7.75%. MDT trades at 17× P/E versus a 30× peer median. That gap contrasts with expectations that look modest versus our growth view. The specific risk is a 20% next-quarter miss probability. The peer gap means the lower multiple still needs support from execution. Peer multiples imply a price roughly in line with where it trades (about fair). Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-29. MDT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 30 analysts currently covering MDT (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for MDT in the last 4 months.
Continue this research
Compare MDT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MDT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put MDT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive growth in key franchises and new product launches
Positive analyst coverage supports growth in key franchises.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $97.11
The last 12 months of price, then the range of analyst 12-month targets from today’s $97.11.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Increase dividend with long-term shareholder return focus
Dividend streak challenge may impact long-term shareholder returns.
Advances: Drive growth in key franchises and new product launches
Regulatory clearance supports growth in key franchises.
Advances: Drive growth in key franchises and new product launches
Positive outlook on diabetes product cycle supports growth in key franchises.
Advances: Achieve and accelerate organic revenue growth
Increased outlook indicates strong organic revenue growth.
Advances: Drive growth in key franchises and new product launches
AI maternal health push aligns with new product launches.
Advances: Drive growth in key franchises and new product launches
AI and targeted M&A align with growth in key franchises.
Advances: Drive growth in key franchises and new product launches
New product lineup drives growth in key franchises.
